
New coverage from disAMR highlights findings from our recent antimicrobial resistance (AMR) research presented by Duane Schulthess (@DuaneSchulthess; CEO, Vital Transformation) at IDWeek 2026. Using hospital EHR records, our study examined 50,189 patients with sepsis, hospital-acquired pneumonia, or complicated urinary tract infection. After accounting for measured patient differences, resistance was associated with an additional median hospital cost of $21,453 (2025 USD) and about four extra median hospital days per infection. Our national model projects annual U.S. hospital costs associated with resistant infections could increase from approximately $31 billion in 2025 to $52 billion by 2045. These findings highlight the growing pressure AMR could place on hospital resources and the importance of investing in prevention, diagnostics, and treatments. #AMR #AntimicrobialResistance #HealthEconomics @VitalTransform @IDWeekmtg #IDWeek2026









